Q-omics provides the consensus-scored DNASE1 profile across patient tissues and cancer cell-line models. DNASE1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DNASE1 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, DNASE1 RNA expression shows 20,718 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where DNASE1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNASE1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNASE1 survival associations across molecular data types. DNASE1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNASE1 RNA expression–survival associations across cancer types. High DNASE1 expression shows unfavorable associations in KIRC and ACC, but favorable associations in HNSC, PAAD, THYM and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for DNASE1 RNA expression.
This table summarizes DNASE1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DNASE1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNASE1 shows lower tumor expression in KIRC, KIRP and THCA and higher tumor expression in COAD, LIHC and LUAD. The KIRC box plot shows higher DNASE1 RNA expression in normal versus tumor tissue (log2 FC = −2.732, t-test p < 0.001).
This table shows molecular features associated with DNASE1 in patient tissues and cancer cell lines. In patient samples, DNASE1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DNASE1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
